Stockreport

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus [Yahoo! Finance]

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at F [Read more]